Status:
COMPLETED
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Hypercholesterolemia
Eligibility:
All Genders
35-79 years
Phase:
PHASE4
Brief Summary
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk fact...
Eligibility Criteria
Inclusion
- Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women)
Exclusion
- Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment.
- Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
1531 Patients enrolled
Trial Details
Trial ID
NCT00407537
Start Date
March 1 2007
End Date
October 1 2009
Last Update
January 28 2021
Active Locations (125)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Desamparados, Provincia de San José, Costa Rica
2
Pfizer Investigational Site
Heredia, Costa Rica
3
Pfizer Investigational Site
San José, Costa Rica
4
Pfizer Investigational Site
Breznički Hum, Croatia, 42225